Filana Therapeutics, Inc
NASDAQ:FLNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Filana Therapeutics, Inc
Change in Working Capital
Filana Therapeutics, Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Filana Therapeutics, Inc
NASDAQ:FLNA
|
Change in Working Capital
$38.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
164%
|
CAGR 10-Years
37%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Change in Working Capital
-$12.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Change in Working Capital
-$455m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Change in Working Capital
-$5.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Change in Working Capital
-$7B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-39%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Change in Working Capital
-$8.1B
|
CAGR 3-Years
-2 063%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-22%
|
|
Filana Therapeutics, Inc
Glance View
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
See Also
What is Filana Therapeutics, Inc's Change in Working Capital?
Change in Working Capital
38.2m
USD
Based on the financial report for Dec 31, 2025, Filana Therapeutics, Inc's Change in Working Capital amounts to 38.2m USD.
What is Filana Therapeutics, Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
37%
